Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology · Phase I

Oncology programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs 1,319

Quick answer

Oncology Phase I programs: NovaPharmaNews indexes 1,319 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Pipeline programs

Page 11 of 28

  1. Cobimetinib

    Cardiff Oncology

    Locally Advanced Pancreatic Ductal Adenocarcinoma

    phase 1 small molecule active

    1 trial

  2. Comparison between ABP 234 and Keytruda® (Pembrolizumab)

    Amgen

    Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

    phase 1 other active

    1 trial

  3. Concurrent chemotherapy

    Sun Yat-sen University

    Locally Advanced Lung Carcinoma

    phase 1 small molecule completed

    1 trial

  4. Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion

    The First People's Hospital of Lianyungang

    Diffuse Large B Cell Lymphoma (DLBCL)

    phase 1 small molecule active

    1 trial

  5. Control Group

    Tvardi Therapeutics

    Squamous Cell Carcinoma of Head and Neck

    phase 1 small molecule terminated

    1 trial

  6. Cosibelimab

    TG THERAPEUTICS, INC.

    B-cell Non Hodgkin Lymphoma

    phase 1 small molecule terminated

    1 trial

  7. Custirsen, paclitaxel and carboplatin

    Teva Pharma GmbH

    Cancer

    phase 1 small molecule completed

    1 trial

  8. Cyclophosphamide

    Iovance Biotherapeutics B.V.

    Locally Advanced Melanoma

    phase 1 small molecule active

    1 trial

  9. Cyclophosphamide

    Nektar Therapeutics UK Limited

    Recurrent Diffuse Large B-Cell Lymphoma

    phase 1 small molecule active

    1 trial

  10. Cyclophosphamide

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 1 small molecule active

    1 trial

  11. Cyclophosphamide and Fludarabine

    Chongqing Precision Biotech Co., Ltd

    Lung Cancer, Nonsmall Cell, Recurrent

    phase 1 small molecule active

    1 trial

  12. D-FR-60010-015

    Ipsen

    Metastatic Pancreatic Adenocarcinoma

    phase 1 other active

    1 trial

  13. D0816C00025

    AstraZeneca AB

    solid tumors

    phase 1 small molecule active

    1 trial

  14. D702EC00001

    AstraZeneca AB

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  15. D8530C00001

    AstraZeneca AB

    "Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer"

    phase 1 other active

    1 trial

  16. D8990C00001

    AstraZeneca AB

    Platinum-resistant recurrent (PRR) ovarian cancer, Platinum-sensitive recurrent (PSR) ovarian cancer, Lung Adenocarcinoma, and endometrial cancer.

    phase 1 other active

    1 trial

  17. D8991C00002

    AstraZeneca AB

    Ovarian cancer Primary peritoneal cancer Fallopian tube cancer

    phase 1 other active

    1 trial

  18. D907HC00001

    AstraZeneca AB

    • Non-small cell lung cancer (Stage III, unresectable) • Small cell lung cancer (Limited stage) • Hepatocellular carcinoma (Unresectable) • Advanced or Metastatic non-small cell lung cancer

    phase 1 small molecule active

    1 trial

  19. D926FC00001

    AstraZeneca AB

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 1 small molecule active

    1 trial

  20. D933IC00001

    AstraZeneca AB

    Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 1 other active

    1 trial

  21. D9470C00001

    AstraZeneca AB

    CD123-Positive Hematological Malignancies: Module 1 focuses on R/R Acute Myeloid Leukemia and R/R Myelodysplastic Syndrome.

    phase 1 other active

    1 trial

  22. D967JC00002

    AstraZeneca AB

    Metastatic Breast Cancer

    phase 1 small molecule active

    1 trial

  23. D967YC00001

    AstraZeneca AB

    Advanced or metastatic non-squamous non-small lung cancer (mNSCLC) with human epidermal growth factor receptor 2 (HER2) overexpression (OE)

    phase 1 other active

    1 trial

  24. DCVac-L

    NORTHWEST BIOTHERAPEUTICS INC

    Ovarian Cancer

    phase 1 mab completed

    1 trial

  25. DHAP

    Takeda

    Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  26. DPH001-01

    Lacuna Pharma Pty Ltd

    Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.

    phase 1 other active

    1 trial

  27. DPH001-01

    Lacuna Pharma Pty Ltd

    Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.

    phase 1 other active

    1 trial

  28. DS-1205c

    Daiichi Sankyo

    Non-small Cell Lung Cancer (NSCLC)

    phase 1 small molecule terminated

    1 trial

  29. DS1062-A-U102

    Daiichi Sankyo

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  30. DS3201-324

    Daiichi Sankyo

    This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.

    phase 1 small molecule active

    1 trial

  31. DS8201-A-U106

    Daiichi Sankyo

    Locally advanced/metastatic breast or non-small cell lung cancer

    phase 1 other active

    1 trial

  32. DT2216

    United Therapeutics Europe Ltd

    Ovarian Cancer

    phase 1 small molecule active

    1 trial

  33. Darlifarnib

    Kura Oncology

    Solid Tumors With HRAS Alterations

    phase 1 small molecule active

    1 trial

  34. Daunorubicin

    Protara Therapeutics

    Acute Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  35. Debio 0123-102

    Alphapharm Pty Ltd

    Arm A: Diagnosed with uterine serous carcinoma (USC) Arm B: Diagnosed with recurrent or progressive, high-grade epithelial ovarian cancer (EOC) with cyclin E1-driven selection Arm C: Diagnosed with solid tumor with biomarker-driven selection

    phase 1 other active

    1 trial

  36. Debio 0123-106

    Alphapharm Pty Ltd

    Advanced solid tumors with CCNE1 amplification or deleterious mutations in FBXW7 or other proprietary gene

    phase 1 small molecule active

    1 trial

  37. Debio 0123-SCLC-104

    Alphapharm Pty Ltd

    Small cell lung cancer

    phase 1 other active

    1 trial

  38. Debio0123-101

    Alphapharm Pty Ltd

    Patients with tumors

    phase 1 other active

    1 trial

  39. Decitabine

    Foghorn Therapeutics

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  40. Demcizumab

    Mereo BioPharma Group plc

    Primary Peritoneal Carcinoma

    phase 1 small molecule terminated

    1 trial

  41. Demcizumab

    Mereo BioPharma Group plc

    Non Small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

  42. Demcizumab

    Mereo BioPharma Group plc

    Locally Advanced or Metastatic Solid Tumors

    phase 1 small molecule completed

    1 trial

  43. Dendritic Cell (DC1) Vaccine

    VACCINEX, INC.

    HER2-positive Breast Cancer

    phase 1 mab active

    1 trial

  44. Dendritic Cell Vaccination

    Quantum Biopharma

    Metastatic Breast Cancer

    phase 1 mab active

    1 trial

  45. Docetaxel

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 1 small molecule completed

    1 trial

  46. Docetaxel

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  47. Dociparstat sodium

    BRIGHT MINDS BIOSCIENCES INC.

    Acute Myeloid Leukemia

    phase 1 small molecule completed

    1 trial

  48. Domvanalimab

    Arcus Biosciences

    Solid Tumor, Unspecified, Adult

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many oncology Phase I programs exist?

1,319 programs match both the therapeutic area and stage filters in our published index.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.